Robert C Newton
Overview
Explore the profile of Robert C Newton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silverman I, Hollebecque A, Friboulet L, Owens S, Newton R, Zhen H, et al.
Cancer Discov
. 2020 Nov;
11(2):326-339.
PMID: 33218975
Pemigatinib, a selective FGFR1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring fusions/rearrangements, and has gained regulatory approval in the United States....
2.
Gibney G, Hamid O, Lutzky J, Olszanski A, Mitchell T, Gajewski T, et al.
J Immunother Cancer
. 2019 Mar;
7(1):80.
PMID: 30894212
Background: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with...
3.
Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart M, et al.
Gynecol Oncol
. 2017 Jul;
146(3):484-490.
PMID: 28698009
Objective: Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat versus tamoxifen in patients...
4.
Beatty G, ODwyer P, Clark J, Shi J, Bowman K, Scherle P, et al.
Clin Cancer Res
. 2017 Jan;
23(13):3269-3276.
PMID: 28053021
Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance. This first-in-human phase I study investigated the...
5.
Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al.
Blood
. 2012 Mar;
119(20):4614-8.
PMID: 22422826
We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg...
6.
Liu X, Wang Q, Yang G, Marando C, Koblish H, Hall L, et al.
Clin Cancer Res
. 2011 Sep;
17(22):7127-38.
PMID: 21918175
Purpose: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target. This study describes the preclinical characterization...
7.
Liu X, Newton R, Scherle P
Expert Opin Investig Drugs
. 2011 Jul;
20(9):1225-41.
PMID: 21740293
Introduction: The aberrantly upregulated c-mesenchymal-epithelia transition factor (c-MET) signaling pathway has been considered to be an attractive target for cancer intervention owing to the important roles it plays in tumor...
8.
Fridman J, Scherle P, Collins R, Burn T, Neilan C, Hertel D, et al.
J Invest Dermatol
. 2011 Jun;
131(9):1838-44.
PMID: 21677670
JAKs are required for signaling initiated by several cytokines (e.g., IL-4, IL-12, IL-23, thymic stromal lymphopoietin (TSLP), and IFNγ) implicated in the pathogenesis of inflammatory skin diseases such as psoriasis...
9.
Trujillo J, Huang W, Hughes R, Rogier D, Turner S, Devraj R, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(6):1827-31.
PMID: 21316220
This report describes the design and synthesis of a series of CCR2 antagonists incorporating novel non-aryl/heteroaryl RHS (right hand side) motifs. Previous SAR in the area has suggested an aryl/heteroaryl...
10.
Fridman J, Scherle P, Collins R, Burn T, Li Y, Li J, et al.
J Immunol
. 2010 Apr;
184(9):5298-307.
PMID: 20363976
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis. Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug...